BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 35217212)

  • 21. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Battipaglia G; Labopin M; Hamladji RM; Blaise D; Chevallier P; Brissot E; Gerbitz A; Socié G; Afanasyev B; Ciceri F; Meijer E; Koc Y; Cornelissen JJ; Huynh A; Ozdogu H; Maertens J; Paul F; Labussière-Wallet H; Ruggeri A; Aljurf M; Bazarbachi A; Savani B; Nagler A; Mohty M
    Cancer; 2021 Jan; 127(2):209-218. PubMed ID: 33119152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Giebel S; Labopin M; Salmenniemi U; Socié G; Bondarenko S; Blaise D; Kröger N; Vydra J; Grassi A; Bonifazi F; Czerw T; Anagnostopoulos A; Lioure B; Ruggeri A; Savani B; Spyridonidis A; Sanz J; Peric Z; Nagler A; Ciceri F; Mohty M
    Cancer; 2023 Dec; 129(23):3735-3745. PubMed ID: 37658621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation.
    Miyao K; Kuwatsuka Y; Murata M; Nagafuji K; Teshima T; Takeuchi Y; Shiratori S; Najima Y; Uchida N; Tanaka M; Sawa M; Ota S; Fukuda T; Ozawa Y; Kako S; Kawakita T; Ara T; Tanaka J; Kanda Y; Atsuta Y; Kanda J; Terakura S;
    Transplant Cell Ther; 2022 Mar; 28(3):153.e1-153.e11. PubMed ID: 34954151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
    Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
    Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network Meta-Analysis.
    Gagelmann N; Ayuk F; Wolschke C; Kröger N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2184-2191. PubMed ID: 28864138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
    Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
    Chakupurakal G; Freudenberger P; Skoetz N; Ahr H; Theurich S
    Cochrane Database Syst Rev; 2023 Jun; 6(6):CD009159. PubMed ID: 37341189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation?
    Heelan F; Mallick R; Bryant A; Radhwi O; Atkins H; Huebsch L; Bredeson C; Allan D; Kekre N
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1298-1302. PubMed ID: 32165325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-transplant CD69+ extracellular vesicles are negatively correlated with active ATLG serum levels and associate with the onset of GVHD in allogeneic HSCT patients.
    Storci G; Barbato F; Ricci F; Tazzari PL; De Matteis S; Tomassini E; Dicataldo M; Laprovitera N; Arpinati M; Ursi M; Maffini E; Campanini E; Dan E; Manfroi S; Santi S; Ferracin M; Bonafe M; Bonifazi F
    Front Immunol; 2022; 13():1058739. PubMed ID: 36713433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
    Yao JM; Otoukesh S; Kim H; Yang D; Mokhtari S; Samara Y; Blackmon A; Arslan S; Agrawal V; Pourhassan H; Amanam I; Ball B; Koller P; Salhotra A; Becker P; Curtin P; Artz A; Aldoss I; Ali H; Stewart F; Smith E; Stein A; Marcucci G; Forman SJ; Nakamura R; Al Malki MM
    Transplant Cell Ther; 2023 Aug; 29(8):515.e1-515.e7. PubMed ID: 37182736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytokine profiling during conditioning in haploidentical stem cell transplantation and its prognostic impact on early transplant outcomes.
    Li N; Zhao C; Ma R; Lou R; Liu XJ; Zheng FM; Wang JZ; Wang Y; Huang XJ; Sun YQ
    Transpl Immunol; 2023 Jun; 78():101830. PubMed ID: 36972853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing Antithymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Based on Recipient Absolute Lymphocyte Count.
    Kennedy VE; Chen H; Savani BN; Greer J; Kassim AA; Engelhardt BG; Goodman S; Sengsayadeth S; Chinratanalab W; Jagasia M
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):150-155. PubMed ID: 28864139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antithymocyte globulin for GVHD prophylaxis in allogeneic hematopoietic stem cell transplantation].
    Shiratori S
    Rinsho Ketsueki; 2021; 62(8):1265-1274. PubMed ID: 34497215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of patients with hematological malignancies who undergo unrelated donor hematopoietic stem cell transplantation with ATG-Fresenius versus ATG-Genzyme.
    Wang L; Kong P; Zhang C; Gao L; Zhu L; Liu J; Gao S; Chen T; Liu H; Yao H; Liu Y; Feng Y; Zhao L; Li Y; Gao L; Zhang X
    Ann Hematol; 2023 Jun; 102(6):1569-1579. PubMed ID: 37097455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia.
    Chen X; Wei J; Huang Y; He Y; Yang D; Zhang R; Jiang E; Ma Q; Zhai W; Yao J; Zhang G; Feng S; Han M
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):86-90. PubMed ID: 29032265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.
    Butera S; Cerrano M; Brunello L; Dellacasa CM; Faraci DG; Vassallo S; Mordini N; Sorasio R; Zallio F; Busca A; Bruno B; Giaccone L
    Ann Hematol; 2021 Jul; 100(7):1837-1847. PubMed ID: 33948721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
    Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
    J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
    Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of peripheral blood stem cell transplantation patients from HLA-mismatched unrelated donor with antithymocyte globulin (ATG)-Thymoglobulin versus ATG-Fresenius: a single-center study.
    Huang W; Zhao X; Tian Y; Cao T; Li Y; Liu Z; Jing Y; Wang S; Gao C; Yu L
    Med Oncol; 2015 Feb; 32(2):465. PubMed ID: 25588925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.